Lonza, Chr. Hansen forming CDMO for live biotherapeutics

Lonza and Chr. Hansen formed a joint venture to establish a contract development and manufacturing organization for end-to-end manufacturing of live biotherapeutics, including microbiome products.

Chr. Hansen A/S (Hoersholm, Denmark) and Lonza Group Ltd. (SIX:LONN) will evenly split a three-year €90 million ($101.2 million) investment to build the JV's cGMP facilities in Hoersholm and Basel...